Front. Endocrinol., 29 April 2024 | Sec. Translational and Clinical Endocrinology | Volume 15 – 2024 The ELISA with the vasoinhibin monoclonal antibody (Vi-mab) was evaluated for cross-reactivity with prolactin
Continue readinghttps://www.communications-in-prolactin-research.com/article/id/3
Continue readingAnti-vasoinhibin monoclonal antibodies (Vi-Mab) are commercially available at Davids Biotechnologie GmbH (Regensburg, Germany). https://davids-science.de/en/p/vasoinhibin-monoclonal-antibody-mouse-monoclonal-or-vi-mab
Continue readingCommunications in Prolactin Research (CPR) is a new, international, peer-reviewed, open access biomedical specialty journal devoted to publishing articles and scientific communications concerning the hormone prolactin. The following article types
Continue reading
orcid.org/0000-0002-1989-8645